Glory Health Industry Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Glory Health Industry.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Real Estate croissance des bénéfices	21.1%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

We Discuss Why Glory Health Industry Limited's (HKG:2329) CEO Compensation May Be Closely Reviewed

Jun 21

We Think Shareholders May Want To Consider A Review Of Guorui Properties Limited's (HKG:2329) CEO Compensation Package

Jun 23

Guorui Properties (HKG:2329) Has A Somewhat Strained Balance Sheet

May 13

Guorui Properties'(HKG:2329) Share Price Is Down 73% Over The Past Five Years.

Jan 31

Should You Use Guorui Properties's (HKG:2329) Statutory Earnings To Analyse It?

Jan 10

What Kind Of Shareholders Hold The Majority In Guorui Properties Limited's (HKG:2329) Shares?

Dec 20

Guorui Properties (HKG:2329) Has A Somewhat Strained Balance Sheet

Dec 03

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Glory Health Industry n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

SEHK:2329 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2024	2,037	-356	36	100	N/A
3/31/2024	2,272	-460	244	306	N/A
12/31/2023	2,506	-564	452	513	N/A
9/30/2023	2,461	-531	189	276	N/A
6/30/2023	2,415	-497	-74	40	N/A
3/31/2023	3,160	-705	170	323	N/A
12/31/2022	3,905	-913	413	606	N/A
9/30/2022	5,087	-817	1,593	1,746	N/A
6/30/2022	6,270	-721	2,773	2,886	N/A
3/31/2022	8,084	-246	3,419	3,616	N/A
12/31/2021	9,898	228	4,066	4,345	N/A
9/30/2021	9,460	261	4,620	4,969	N/A
6/30/2021	9,021	294	5,174	5,594	N/A
3/31/2021	7,395	196	4,920	5,266	N/A
12/31/2020	5,769	99	4,666	4,938	N/A
9/30/2020	6,705	301	4,712	4,920	N/A
6/30/2020	7,641	502	4,759	4,901	N/A
3/31/2020	7,867	681	5,069	5,204	N/A
12/31/2019	8,093	860	5,378	5,507	N/A
9/30/2019	8,121	943	4,766	5,041	N/A
6/30/2019	8,149	1,027	4,155	4,576	N/A
3/31/2019	7,381	1,018	2,230	2,659	N/A
12/31/2018	6,612	1,009	306	742	N/A
9/30/2018	6,728	1,335	-453	0	N/A
6/30/2018	6,844	1,662	-1,211	-741	N/A
3/31/2018	6,816	1,706	N/A	-1,991	N/A
12/31/2017	6,787	1,750	N/A	-3,240	N/A
9/30/2017	6,674	1,474	N/A	-3,925	N/A
6/30/2017	6,561	1,198	N/A	-4,609	N/A
3/31/2017	7,298	1,380	N/A	-3,017	N/A
12/31/2016	8,035	1,563	N/A	-1,425	N/A
9/30/2016	7,807	1,457	N/A	-2,252	N/A
6/30/2016	7,580	1,351	N/A	-3,080	N/A
3/31/2016	7,047	1,306	N/A	-2,479	N/A
12/31/2015	6,514	1,261	N/A	-1,879	N/A
9/30/2015	6,060	1,380	N/A	-719	N/A
6/30/2015	5,606	1,500	N/A	442	N/A
3/31/2015	5,442	1,225	N/A	-94	N/A
12/31/2014	5,279	951	N/A	-630	N/A
9/30/2014	5,688	896	N/A	N/A	N/A
6/30/2014	6,097	841	N/A	N/A	N/A
3/31/2014	6,466	1,537	N/A	N/A	N/A
12/31/2013	6,835	2,234	N/A	33	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de 2329 est supérieure au taux d'épargne ( 2.3% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de 2329 devraient croître plus rapidement que le marché Hong Kong

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de 2329 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de 2329 devraient croître plus rapidement que le marché Hong Kong.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de 2329 devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 2329 devrait être élevé dans 3 ans

Glory Health Industry Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Glory Health Industry Limited Provides Earnings Guidance for Six Months Ended June 30, 2022

Recent updates

First half 2024 earnings released: CN¥0.013 loss per share (vs CN¥0.06 loss in 1H 2023)

Glory Health Industry Limited to Report First Half, 2024 Results on Aug 30, 2024

We Discuss Why Glory Health Industry Limited's (HKG:2329) CEO Compensation May Be Closely Reviewed

Glory Health Industry Limited, Annual General Meeting, Jun 28, 2024

Full year 2023 earnings released: CN¥0.13 loss per share (vs CN¥0.20 loss in FY 2022)

Glory Health Industry Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Glory Health Industry Limited Appoints Lam Yuen Ling Eva as Company Secretary

Glory Health Industry Limited Announces the Resignation of Liu Chengjiang as Independent Non-Executive Director, Chairman of the Internal Control Committee and Member of the Audit Committee

Glory Health Industry (HKG:2329) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.15 loss in 1H 2022)

Glory Health Industry Limited Announces Resignation of Lai Siming as an Independent Non-Executive Director

Glory Health Industry Limited to Report First Half, 2023 Results on Aug 31, 2023

Now 32% undervalued after recent price drop

Glory Health Industry Limited Announces Resignation of Kwong Yin Ping Yvonne as Joint Company Secretary and Authorised Representative, Effective July 1, 2023

Glory Health Industry Limited Announces Retirement of Luo Zhenbang as Independent Non-Executive Director

Glory Health Industry Limited Announces Resignation of Zheng Jin as Joint Company Secretary and an Authorised Representative

Health Check: How Prudently Does Glory Health Industry (HKG:2329) Use Debt?

Glory Health Industry Limited, Annual General Meeting, Jun 30, 2023

Now 21% undervalued after recent price drop

Glory Health Industry Limited Appoints Liu Chengjiang as Independent Non-Executive Director, Chairman of Internal Control Committee and Member of Audit Committee

Now 21% undervalued after recent price drop

A Look At The Fair Value Of Glory Health Industry Limited (HKG:2329)

Full year 2022 earnings released: CN¥0.20 loss per share (vs CN¥0.051 profit in FY 2021)

Glory Health Industry Limited Announces Resignation of Ms. Chen Jingru as Independent Non-Executive Director, Chairman of the Internal Control Committee of the Company and Member of the Audit Committee

Less than half of directors are independent

Glory Health Industry (HKG:2329) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.06 profit in 1H 2021)

Glory Health Industry Limited Provides Earnings Guidance for Six Months Ended June 30, 2022

Glory Health Industry Limited to Report First Half, 2022 Results on Aug 31, 2022

Less than half of directors are independent

We Think Guorui Properties (HKG:2329) Is Taking Some Risk With Its Debt

Full year 2021 earnings released: EPS: CN¥0.051 (vs CN¥0.022 in FY 2020)

Guorui Properties Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Less than half of directors are independent

First half 2021 earnings released: EPS CN¥0.06 (vs CN¥0.016 in 1H 2020)

Here's Why Guorui Properties (HKG:2329) Is Weighed Down By Its Debt Load

We Think Shareholders May Want To Consider A Review Of Guorui Properties Limited's (HKG:2329) CEO Compensation Package

Guorui Properties (HKG:2329) Has A Somewhat Strained Balance Sheet

Full year 2020 earnings released: EPS CN¥0.022 (vs CN¥0.19 in FY 2019)

Chairman & President recently bought HK$1.6m worth of stock

Full year 2020 earnings released: EPS CN¥0.022 (vs CN¥0.19 in FY 2019)

Guorui Properties Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: HK$0.73

Guorui Properties'(HKG:2329) Share Price Is Down 73% Over The Past Five Years.

Should You Use Guorui Properties's (HKG:2329) Statutory Earnings To Analyse It?

New 90-day low: HK$0.74

What Kind Of Shareholders Hold The Majority In Guorui Properties Limited's (HKG:2329) Shares?

New 90-day low: HK$0.83

Guorui Properties (HKG:2329) Has A Somewhat Strained Balance Sheet

New 90-day low: HK$0.84

New 90-day low: HK$0.94

First half earnings released

New 90-day low - HK$1.10

First half earnings released

Guorui Properties Limited to Report First Half, 2020 Results on Aug 31, 2020

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance